From: First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study
No. of Pts
No. of Responders
Percent of Pts
95% CI
Evaluable patients
35
14
40.0%
(23.8%–56.2%)
Prior anthracycline exposure
Yes
22
6
27.3%
(8.7%–45.9%)
No
13
8
61.5%
(35.1%–88.0%)